New cancer research facility aims to accelerate personalised cancer medicine in Queensland

Diamantina_Opening_2The opening of a new cancer genomics centre at UQ Diamantina Institute at TRI means Queensland is now home to the largest and most sophisticated genome sequencing facility in the southern hemisphere.

Funded by the ACRF ($2 million), the Diamantina Individualised Oncology Care Centre (DIOCC) will be an innovative, world leading center of near-patient cancer genomics research.

“The way forward for cancer research is to really prioritise translational, patient-focused outcomes, and that is why the Australian Cancer Research Foundation is so proud to support this new centre at TRI,” said ACRF Chairman, Mr Tom Dery.

DIOCC will house state of the art genomics, proteomics and metabolomics technology. This technology will enable cutting edge research primarily into skin, blood and breast cancers.

The research to be undertaken within DIOCC will focus on understanding disease causes, improving diagnosis and treatment development. It will also allow for the development of protocols to implement the use of these new technologies in clinical practice.

As a collaboration of clinicians and scientists working in near patient cancer research, DIOCC offers a unique opportunity to foster translational research.

It brings together research and clinical groups across the Princess Alexandra Hospital (PAH) campus, including clinical services in Oncology, Haematology and Dermatology, The University of Queensland Schools of Medicine and Pharmacy and the Translational Research Institute (TRI).

The new facility was opened during an official ceremony on Thursday 31 July 2014.[/vc_column_text][/vc_column][/vc_row][vc_gallery type=”flexslider_fade” interval=”0″ images=”22170,22167,22172,22168,22171,22169″ onclick=”link_image” custom_links_target=”_self” img_size=”large”][/vc_column][/vc_row]